CGAS and neoplasm: DNA-containing EVs from anti-tumor topotecan (DNA topoisomerase I inhibitor)-treated breast cancer cells activate the cytokine release of dendritic cells by cGAS-STING signaling activation in cytosolic DNA-mediated innate immune responses, leading to a more robust anti-tumor immune response (108).